Want to see HK:1450 full AI Analyst Report?
1450 Stock Chart & Stats
HK$0.82
-HK$0.01(-1.22%)
At close: 4:00 PM EDT
HK$0.82
-HK$0.01(-1.22%)
Day’s Range― - ―
52-Week RangeHK$0.68 - HK$1.26
Previous CloseN/A
Volume984.00K
Average Volume (3M)1.96M
Market Cap
HK$1.17B
Enterprise ValueHK$1.32K
Total Cash (Recent Filing)HK$360.53M
Total Debt (Recent Filing)HK$93.33M
Price to Earnings (P/E)10.5
Beta0.54
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.02%
Share Statistics
EPS (TTM)0.07
Shares Outstanding1,407,203,100
10 Day Avg. Volume2,198,140
30 Day Avg. Volume1,964,156
Financial Highlights & Ratios
PEG Ratio1.42
Price to Book (P/B)2.65
Price to Sales (P/S)0.95
P/FCF Ratio4.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.22
Revenue Forecast (FY)HK$2.33B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained, multi‑year revenue scaling establishes a larger recurring base and demonstrates product–market fit across cycles. Growth through 2025 supports capacity to invest in product and sales, amortize fixed costs, deepen customer relationships, and improve long‑term cash flow visibility.
Balance Sheet / LeverageMeaningful reduction in leverage with a larger equity base materially improves financial flexibility, lowering interest burden and refinancing risk. Combined with healthier ROE in recent years, this strengthens the firm's ability to fund organic growth, pursue M&A, or sustain dividends without excess external financing.
Cash GenerationReturn to strongly positive operating and free cash flow in 2025 shows improved cash conversion ability, enabling internal funding for operations, CAPEX, and shareholder returns. More reliable FCF enhances balance sheet resilience, reduces reliance on debt, and supports strategic investments over the medium term.
Bears Say
Margin CompressionMaterial compression of gross, operating and net margins since the 2023 peak indicates rising cost pressure or pricing weakness. That reduces internal funding capacity, lowers incremental returns on sales, and can structurally depress return on invested capital and cash generation unless cost or pricing dynamics are reversed.
Cash-Flow VolatilityOperating and free cash flow have been inconsistent, with negative results in 2022 and 2024, increasing execution and working‑capital timing risk. Episodic cash deficits can force reliance on external financing at unfavorable terms, disrupting steady investment, dividend policy and long‑range planning.
Volatile Returns / Transition RiskWide swings in historical returns and a transitioning capital structure indicate the business model and profitability are not yet stable. Such volatility complicates forecasting, raises the chance of mean reversion, and increases uncertainty around sustainable returns and cost of capital for the medium term.
Century Sage Scientific Holdings Ltd News
1450 FAQ
What was Century Sage Scientific Holdings Ltd’s price range in the past 12 months?
Century Sage Scientific Holdings Ltd lowest stock price was HK$0.68 and its highest was HK$1.26 in the past 12 months.
What is Century Sage Scientific Holdings Ltd’s market cap?
Century Sage Scientific Holdings Ltd’s market cap is HK$1.17B.
When is Century Sage Scientific Holdings Ltd’s upcoming earnings report date?
Century Sage Scientific Holdings Ltd’s upcoming earnings report date is Aug 21, 2026 which is in 5 days.
How were Century Sage Scientific Holdings Ltd’s earnings last quarter?
Century Sage Scientific Holdings Ltd released its earnings results on Mar 26, 2026. The company reported HK$0.026 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Century Sage Scientific Holdings Ltd overvalued?
According to Wall Street analysts Century Sage Scientific Holdings Ltd’s price is currently Overvalued.
Does Century Sage Scientific Holdings Ltd pay dividends?
Century Sage Scientific Holdings Ltd pays a Notavailable dividend of HK$0.05 which represents an annual dividend yield of 6.02%. See more information on Century Sage Scientific Holdings Ltd dividends here
What is Century Sage Scientific Holdings Ltd’s EPS estimate?
Century Sage Scientific Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Century Sage Scientific Holdings Ltd have?
Century Sage Scientific Holdings Ltd has 1,407,203,100 shares outstanding.
What happened to Century Sage Scientific Holdings Ltd’s price movement after its last earnings report?
Century Sage Scientific Holdings Ltd reported an EPS of HK$0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Century Sage Scientific Holdings Ltd?
Currently, no hedge funds are holding shares in HK:1450
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Century Sage Scientific Holdings Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.08%
12-Months-Change
Fundamentals
Return on Equity
6.02%
Trailing 12-Months
Asset Growth
7.15%
Trailing 12-Months
Company Description
Century Sage Scientific Holdings Ltd
Be Friends Holding Ltd. functions as an investment firm, concentrating on providing integrated hardware and software solutions tailored for all-media applications. The company's activities are organized into distinct divisions: New Media Services, Application Solutions, System Maintenance Services, and the commercialization of its proprietary offerings. Established by Chi Sum Lo in 2007, its main corporate base is located in Hangzhou, China.
Technical Analysis
Xuan Wu Cloud Technology Holdings Limited
―
Sinopharm Tech Holdings Limited
―
YSB Inc.
―
Zhejiang Taimei Medical Technology Co Ltd Class H
―
Beijing Saimo Technology Co. Ltd. Class H
―